SR9009
SR9009 is a Rev-Erbα agonist. It activates a nuclear receptor that regulates circadian rhythm, fat storage, glucose metabolism, and mitochondrial biogenesis. Rev-Erb controls large portions of the metabolic program that governs when the body burns fat vs. stores it, and how efficiently mitochondria are generated and recycled.
The practical effects mirror the biological role: enhanced fat metabolism, improved endurance, and a metabolic shift toward greater energy expenditure. It does not bind androgen receptors and does not suppress testosterone. It is often grouped with SARMs in discussions but operates through an entirely different pathway.
The major pharmacological limitation is poor oral bioavailability. Animal studies used intraperitoneal injection, and oral absorption in humans appears to be low. This drives some users toward injectable liquid formulations, which have better bioavailability but complicate dosing.
SR9009 is chosen by users interested in endurance and fat oxidation who want to approach it from a circadian/metabolic angle rather than through stimulants, EPO-type pathways, or PPARδ (Cardarine). The non-suppressive profile is attractive, as is the unusual mechanism. Bodybuilders use it in cutting phases; endurance athletes use it for training capacity.
If oral bioavailability is adequate in a given user, the expectation is improved endurance capacity and fat oxidation over several weeks. The response is more variable than with Cardarine, partly because bioavailability is the wild card. Users who switch to injectable forms tend to report more consistent and stronger effects.
Use context
SR9009 represents an interesting approach to metabolic modulation by targeting the circadian machinery rather than hormonal or androgenic pathways. The Rev-Erb system governs fat storage timing, mitochondrial turnover, and metabolic fuel selection in ways that are distinct from anything else in the compound landscape.
The human translation from animal studies is genuinely uncertain, partly because of the bioavailability problem. Most of the compelling data comes from intraperitoneal injection in animals, a route that bypasses the oral absorption issues entirely. Users running oral SR9009 may be getting a fraction of the dose that would be needed to reproduce animal-study effects.
Running oral SR9009 at low doses, experiencing little, and concluding the compound is inactive when the more likely explanation is poor bioavailability. Expecting animal-study level results without accounting for the route-of-administration difference. Not dosing frequently enough when the short half-life means twice-daily minimum dosing is needed even with injectable formulations.
Compared with Cardarine, SR9009 targets a different receptor (Rev-Erb vs PPARδ) but produces overlapping practical effects. Cardarine has better oral bioavailability and more consistent user reports. SR9009 is more interesting mechanistically to users who care about circadian biology. Some users stack both for dual-pathway metabolic coverage. Compared with stimulant-based fat loss (Clenbuterol, yohimbine), SR9009 addresses metabolism differently without the cardiovascular stimulant burden.
Limited human data, so the side-effect profile is not well characterized
Poor oral bioavailability means inconsistent human response to oral dosing
lipid panel
fasting glucose if running extended cycles
Users who require consistent dosing but cannot commit to 3–4x daily administration
Expecting animal-study level results from oral administration without bioavailability acknowledgment